protecting pregnant women from malaria: exploring safety data · dihydroartemisinine-piperaquine...
TRANSCRIPT
Protecting Pregnant women from malaria: exploring safety data Bali | 11 – 12 October 2017
JR Poespoprodjo, MD PhD; Rukhsana Ahmed, MD, Mpaed, PhD
Defeating Malaria Together
Dihydroartemisinine-piperaquine experience in Timika, Papua
• Indonesia is the first country to introduce DP for treatment malaria
• It became policy in March 2006-changed from CQ-SP
• Same time for treatment of 2nd & 3rd trimester pregnancy & infants
• Data available electronically in the hospital
2
DHP exposure
3
0%
10%
20%
30%
40%
50%
60%
2004
_Apr
2004
_Jun
2004
_Aug
2004
_Oct
2004
_Dec
2005
_Feb
2005
_Apr
2005
_Jun
2005
_Aug
2005
_Oct
2005
_Dec
2006
_Feb
2006
_Apr
2006
_Jun
2006
_Aug
2006
_Oct
2006
_Dec
2007
_Feb
2007
_Apr
2007
_Jun
2007
_Aug
2007
_Oct
2007
_Dec
2008
_Feb
2008
_Apr
2008
_Jun
2008
_Aug
2008
_Oct
2008
_Dec
2009
_Feb
2009
_Apr
2009
_Jun
As+Aq
IV Qu
Oral Cq/Qu
IV Art a lone
IV Art+DHP
DHP a lone
March 2006
Safety of artemesinins in first trimester-what is known
• Malaria in 1st trimester is known to be associated with pregnancy loss (miscarriage or stillbirth)
• ACTs more effective than quinine, well tolerated and already widely used in 1st trimester
• Quinine is not well tolerated and poor compliance to 7 day treatment -> untreated malaria
• Safety data is limited but doesn’t indicate any safety signal with artemisinins in humans
• 90% of ACT safety data comes from artemether-lumefantarine
4
First Trimester DHP exposure study
• Rationale: • Has a computerized recording
system in the hospitals • Larger database at our disposal
for data abstraction • Infrastructure and trained staff
experienced in obtaining data in place
• An extension of existing collaboration between Timika research facility and LSTM
5
First trimester DHP exposure study Timika Indonesia
• Objectives • Compare the risk of miscarriage and stillbirths between women treated
with DHP and quinine in 1st trimester • Compare the risk of congenital anomalies in between women treated
with DHP and quinine in 1st trimester • Secondary: assess maternal, fetal and infant morbidity and mortality
outcomes during 8 weeks post-natal period
6
Study design
• Observational record linkage retrospective & prospective component
• Sample size: • Retrospective: 1500 exposures (225 DHP & 1245 quinine) • Prospective: 298 women ( 50 DHP, 248 quinine (
inadvertent)
7
Retrospective cohort-record linkage
8
Exposure
quinine
DP
none
Data source
emergency
delivery
pharmacy
inpatient
Miscarriage Stillbirth
Congenital anomalies
outcome
Prospective cohort
Eligibility criteria
Check gestational age by U/S: < 24 weeks Confirm malaria/fever history (recall), treatment –past 6 months Check medical records for treatment: DP/quinine
Follow-up antenatal visit
Fetal viability h/o fever, malaria Drug treatment
Delivery & post natal
Term/preterm Baby: surface examination for congenital anomalies Birth weight
9
Outcomes of study
• Expected to add to existing safety data • Pregnant women: miscarriage and stillbirths • Newborns: surface congenital anomalies, preterm birth
(babies) • Post-natal: maternal and infant morbidity and mortality
upto 6-8 weeks
10
Acknowledgement
• MMV for funding the study
11
How do you get pregnant, how to get pregnant quickly, positions to get pregnant, want to get pregnan
How to conceive a boy, best ways to get pregnant, tips on how to get pregnant, help getting pregnant